Literature DB >> 17103199

[Therapy of cutaneous metastases of malignant melanoma].

P Rehberger1, S Eppinger, A Stein, J Schmitt.   

Abstract

Malignant melanoma represents a particular challenge for dermatologists and oncologists because of its high and increasing incidence and the poor prognosis of patients with thick primary tumors (T3, T4). In advanced stages of melanoma, cutaneous and subcutaneous metastases have a special significance, as they markedly affect the patient and may lead to a limitation in quality of life. While topical therapy is possible, there are only limited clinical studies. The location, number, size and distribution of skin metastases, involvement of internal organs, age and general condition should be considered in assessing therapeutic options. Especially with solitary, easily accessible metastases, surgical excision represents the therapy of choice. Ablation using CO(2) laser is an alternative. With extensive metastases in just one extremity, isolated limb perfusion (ILP) with melphalan is an option, while multiple, smaller metastases can be irradiated. Further, several chemotherapeutic agents and immune modulators can be used topically, peri- and intralesionally.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17103199     DOI: 10.1007/s00105-006-1253-1

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  41 in total

Review 1.  Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma.

Authors:  Graham Stevens; Michael J McKay
Journal:  Lancet Oncol       Date:  2006-07       Impact factor: 41.316

2.  The carbon dioxide laser in plastic surgery.

Authors:  I Kaplan; R Ger; U Sharon
Journal:  Br J Plast Surg       Date:  1973-10

3.  [The nonspecific epifocal Malek-Mansour immunotherapy of malignant cutaneous melanoma using DNCB].

Authors:  L Illig; E Paul
Journal:  Hautarzt       Date:  1976-12       Impact factor: 0.751

4.  Techniques of regional perfusion.

Authors:  O Creech; E Krementz
Journal:  Surgery       Date:  1966-10       Impact factor: 3.982

5.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

6.  Intralesional therapy of metastatic spreading melanoma with beta-interferon.

Authors:  Harriet Rapprich; Manfred Hagedorn
Journal:  J Dtsch Dermatol Ges       Date:  2006-09       Impact factor: 5.584

7.  Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).

Authors:  Boel Ragnarsson-Olding; Eva Djureen-Mårtensson; Eva Månsson-Brahme; Johan Hansson
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

8.  Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas?

Authors:  P Wolf; E Rieger; H Kerl
Journal:  J Am Acad Dermatol       Date:  1993-01       Impact factor: 11.527

9.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

Authors:  S A Rosenberg; J C Yang; D E White; S M Steinberg
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

10.  Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology.

Authors:  J Overgaard; D Gonzalez Gonzalez; M C Hulshof; G Arcangeli; O Dahl; O Mella; S M Bentzen
Journal:  Lancet       Date:  1995-03-04       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.